Here’s What Boosted Tempus AI (TEM) in Q1
Frontier Capital Management, an investment management company, released its “Frontier Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Tempus Ai Inc. (TEM)
Market is closed
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $60.00 | 5,000 | $300,000.00 | 145,000 | 2025-07-07 | Filing | |
| $62.52 | 625 | $39,075.00 | 26,554 | 2025-07-01 | Filing | |
| $71.16 | 13,606 | $968,202.96 | 15,427,132 | 2025-06-18 | Filing | |
| $70.26 | 51,202 | $3,597,452.52 | 15,440,738 | 2025-06-18 | Filing | |
| $69.17 | 103,155 | $7,135,231.35 | 15,491,940 | 2025-06-18 | Filing |
News See All
Guggenheim Raises Tempus AI (TEM) Price Target, Maintaining Buy Rating
On June 30, 2025, Guggenheim analyst Subbu Nambi reaffirmed a “Buy” rating on Tempus AI, Inc. (NASDAQ:TEM), while raising the firm’s price target from $65.00 to $75.00.
Top 10 Healthcare AI Stocks to Buy According to Hedge Funds
“Healthcare is the most underappreciated AI beneficiary,” said Ark Invest CEO Cathie Wood in a recent statement that’s reverberating across Wall Street.
Tempus AI (TEM) Falters on $400-Million Debt Issue
In a statement, Tempus AI, Inc. (NASDAQ:TEM) said that it plans to raise the funds through a convertible senior notes issuance to qualified institutional buyers.
Tempus AI's Ambry Genetics Leads with Validated 99.5% Accurate Hereditary Cancer Risk Assessment Tool
Tempus AI Inc. (NASDAQ:TEM) is one of the best AI stocks to buy according to hedge funds.
11 Best AI Stocks to Buy According to Hedge Funds
Keith Lerner, co-chief investment officer at Truist Wealth, joined CNBC's "Closing Bell" on June 27 to discuss how the bull market's dominant theme is AI.
Tempus AI, Inc. (TEM): A Bull Case Theory
We came across a bullish thesis on Tempus AI, Inc. on Make Money, Make Time’s Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on TEM.
Why Tempus AI, Inc. (TEM) Skyrocketed On Monday
We recently published a list of These 10 Stocks Blew Past Expectations.
Tempus AI Unveils New Liquid Biopsy Assay for Early Immunotherapy Response Monitoring in Cancer
On Monday, Tempus AI Inc. (NASDAQ:TEM) announced the introduction of xM for treatment response monitoring/TRM.
Tempus AI Expands Tempus One with EHR Integration, New AI Features
On June 1, Tempus AI Inc. (NASDAQ:TEM) announced the expansion of its GenAI clinical assistant, called Tempus One, with direct integration into electronic health record/EHR systems.
Billionaire Hedge Funds
